Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (PREVAIL): results from a randomised, phase 3 trial
Yohann Loriot(Université Paris-Sud), Kurt Miller(Charité - Universitätsmedizin Berlin), Cora N. Sternberg(Carlo Forlanini Hospital), Karim Fizazi(Institut Gustave Roussy), Johann S. de Bono(Royal Marsden Hospital), Simon Chowdhury(St Thomas' Hospital), Celestia S. Higano(University of Washington), Sarah B. Noonberg, Stefan Holmström(Astellas Pharma (Netherlands)), Harry H. Mansbach(San Francisco VA Medical Center), Frank Perabo(Astellas Pharma (United States)), De Phung(Astellas Pharma (United States)), Cristina Ivanescu, Konstantina Skaltsa(Universitat de Barcelona), Tomasz M. Beer(Oregon Health & Science University), Bertrand Tombal(Cliniques Universitaires Saint-Luc)
Cited by 191
Abstract
Related Papers
No related papers found
Powered by citation graph analysis